Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ANGPTL3 Gene Editing: Promise and Prudence
Author(s): Alberto Lorenzatti Added: 2 months ago

Prevention & Chronic Conditions
AHA 25: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Author(s): Stephen Nicholls Added: 6 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses… View more

Prevention & Chronic Conditions
ESC HF 25: CRISPR in ATTR-CM: Hereditary vs Wild-Type
Author(s): Marianna Fontana Added: 1 year ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,… View more

Heart Failure
Oxidative Stress Genes Predict Survival in STEMI
Author(s): Shuo-wen Sun , Xing-jie Wang , Ruo-chen Yan , et al Added: 1 year ago

MI/ACS

Prevention & Chronic Conditions
ACC 25: The MyPEAK-1 Study
Author(s): Milind Y Desai Added: 1 year ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene… View more

Heart Failure
Prevention: What's New at HFA 2025?
Author(s): Harriette Van Spall , Maja Cikes Added: 12 months ago
ESC HF 25 - Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Maja Cikes (University Hospital Centre Zagreb, HR) for an insightful wrap up of the novel data concerning preventive cardiology that was presented at 2025's Heart Failure Congress.Trials discussed include:REDICAE (00:42)FINEARTS HF (02:27)CRISPR Gene Editing with Nexiguran Ziclumeran (05:53)HELIOS B (07:12)RESHAPE… View more

Heart Failure
AHA Scientific Sessions 2025 Late-Breaking and Featured Science Collection
Author(s): Nicolas M Van Mieghem Added: 6 months ago
Stay at the forefront of cardiovascular medicine with our comprehensive video collection from the American Heart Association's Scientific Sessions 2025. Access expert analysis of the most impactful late-breaking trials and featured science shaping clinical practice.Late-Breaker Discussions: Watch Dr Harriette Van Spall break down pivotal clinical trial data and explore its implications for… View more

Intervention

Cardiovascular Kidney Metabolic
AHA 24: Nexiguran Ziclumeran for ATTR-CM
Author(s): Marianna Fontana Added: 1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single… View more

Heart Failure
The Leap Year Gene with Shelley Wood, Bestselling Author & Editor-in-Chief of TCTmd
Added: 1 year ago
In this week’s Parallax, Dr Ankur Kalra welcomes back Shelley Wood, best known for her work in the cardiology community as the editor-in-chief of TCTMD and Editorial Director of CRF. They discuss her work as a creative author and her second novel, The Leap Year Gene of Kit McKinley, set to be published by Harper Collins in Canada and Union Square Press in the US in August 2024.Blending the… View more

Guidelines & Statements
Lipid-lowering Therapies and Lp(a)
Author(s): Stephen Nicholls , Adam J Nelson Added: 2 weeks ago

Prevention & Chronic Conditions